Parkinson's Disease/Movement Disorders News

Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study.

The FDA has granted orphan drug designation to an investigational oral therapeutic for the treatment of Huntington’s disease, according to the manufacturer.

Continuous subcutaneous infusion of foslevodopa/foscarbidopa improved “on” time and reduced “off” time in those with Parkinson’s disease at 52 weeks, with a favorable safety and tolerability profile, per research from Neurology and Therapy.

Healio spoke with Erin Furr Stimming, MD, about recent advancements and FDA approvals in Huntington’s disease.

Healio spoke with Erin Furr Stimming, MD, about greatest areas of unmet need in Huntington’s disease care.

Healio spoke with Erin Furr Stimming, MD, about treatments in the pipeline for Huntington’s disease.

Healio spoke with Erin Furr Stimming, MD, about the impact of Huntington's disease awareness among providers and the general public.

Healio spoke with Erin Furr Stimming, MD, about health disparities that exist in the diagnosis, management, care and outcomes of Huntington’s diseased an how can clinicians address these disparities in their practice.

Healio spoke with Erin Furr Stimming, MD, about risk factors that can be addressed early in Huntington’s disease.

The FDA has granted breakthrough device designation to a Spanish health-tech company for its Intelligent Network Modulation System as an adjunctive therapy for treating Parkinson’s disease.